Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Aug 1;31(15):3142-3149.
doi: 10.1158/1078-0432.CCR-24-4048.

Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller  1   2   3 , Stefanie Hayoz  4 , Daniel Horber  5 , Wolfram Jochum  6 , Sara De Dosso  7   8 , Dieter Koeberle  2   9 , Sabina Schacher  10 , Roman Inauen  11 , Michael Stahl  12 , Thierry Delaunoit  13 , Thomas Ettrich  14 , György Bodoky  15 , Pierre Michel  16   17 , Thibaud Koessler  18   19 , Karin Rothgiesser  4 , Sandra Calmonte  4 , Markus Joerger  5
Affiliations
Clinical Trial

Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller et al. Clin Cancer Res. .

Abstract

Purpose: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated colon cancer.

Patients and methods: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events.

Results: Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27-1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%-92.0%) in the aspirin and 72.9% (90% CI, 55.7%-84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21-1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events.

Conclusions: The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III. See related commentary by Drew et al., p. 3107.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statements: Dr Joerger has advisory roles for Novartis, Astra Zeneca, Basilea Pharmaceutica, Bayer, BMS, Debiopharm, MSD, Roche, and Sanofi, received research funding from Swiss Cancer Research and travel grants from Roche, Sanofi, and Takeda. No other disclosures were reported.

Figures

Figure 1
Figure 1. CONSORT diagram.
Enrollment and distribution of patients in the study.
Figure 2
Figure 2. Screened and accrued patients.
Plot representing the number of screened (in red) and accrued (in blue) patients over time (between April 2016 and November 2020). Of 1’040 patients screened, 112 with PIK3CA-mutant colon cancer were included into the study.
Figure 3
Figure 3. Disease-free survival.
Kaplan-Meier curve of disease-free survival (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue). Abbreviation: HR: hazard ratio
Figure 4
Figure 4. Time to recurrence.
Kaplan-Meier curve of time to recurrence (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue). Abbreviation: HR: hazard ratio
See this image and copyright information in PMC

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. - PubMed
    1. Bailey CE, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150(1):17–22. doi: 10.1001/jamasurg.2014.1756. - DOI - PMC - PubMed
    1. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–1305. - PubMed
    1. Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, et al. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. Ann Oncol. 2019;30(8):1304–1310. - PubMed
    1. Sobrero AF, Puccini A, Shi Q, Grothey A, Andrè T, Shields AF, et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur J Cancer. 2020;138:182–188. - PubMed

Publication types

MeSH terms